368 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Festival honors former Quiksilver CEO Pierre Agnes, lost at sea in 2018 https://www.ocregister.com/2019/10/29/festival-honors-former-quiksilver-ceo-pierre-agnes-lost-at-sea-in-2018/ Oct 29, 2019 - Agnes disappeared during a storm while sailing off the coast of his native France.
Allergan (AGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release http://www.zacks.com/stock/news/590606/allergan-agn-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q3-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-590606 Oct 29, 2019 - Allergan (AGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for AbbVie (ABBV) This Earnings Season? http://www.zacks.com/stock/news/584231/whats-in-the-cards-for-abbvie-abbv-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-584231 Oct 25, 2019 - AbbVie's (ABBV) Q3 sales may have been weighed down by biosimilar competition for Humira in international markets. However, strong growth of oncology drugs might have offset impact of Humira's international sales erosion.
Will Allergan (AGN) Beat Estimates Again in Its Next Earnings Report? http://www.zacks.com/stock/news/584032/will-allergan-agn-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-584032 Oct 25, 2019 - Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
J&J (JNJ) Recalls Baby Powder Batch as FDA Finds Asbestos http://www.zacks.com/stock/news/575752/jj-jnj-recalls-baby-powder-batch-as-fda-finds-asbestos?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-575752 Oct 21, 2019 - J&J (JNJ) voluntarily recalls one lot of its baby powders, which is the subject of numerous lawsuits claiming that its talc-based products contain asbestos that causes cancer.
Editas Inks Deal for Gene Editing Neurological Disease Drugs http://www.zacks.com/stock/news/567847/editas-inks-deal-for-gene-editing-neurological-disease-drugs?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-567847 Oct 16, 2019 - Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
Aclaris Divests Rhofade to EPI Health for $55M, Shares Up http://www.zacks.com/stock/news/563815/aclaris-divests-rhofade-to-epi-health-for-%2455m-shares-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-563815 Oct 14, 2019 - Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.
Wet AMD Space in Focus: New Drug Approvals & Key Advancements http://www.zacks.com/stock/news/557772/wet-amd-space-in-focus-new-drug-approvals-key-advancements?cid=CS-ZC-FT-analyst_blog|industry_focus-557772 Oct 10, 2019 - The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.
IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA http://www.zacks.com/stock/news/539102/intelgenx-igxt-resubmits-nda-for-migraine-candidate-to-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-539102 Sep 27, 2019 - IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.
Top Analyst Reports for Bristol-Myers Squibb, Lockheed Martin & Alphabet http://www.zacks.com/research-daily/531879/top-analyst-reports-for-bristol-myers-squibb-lockheed-martin-alphabet?cid=CS-ZC-FT-research_daily-531879 Sep 23, 2019 - Top Analyst Reports for Bristol-Myers Squibb, Lockheed Martin & Alphabet

Pages: 1234567...37

<Page 2>